Inderjeet Bharaj has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Artificial intelligence in the cath lab: Bridging predictive models and real-time procedural decision support

    by Inderbir Padda, Shirobhi Sharma, Yashendra Sethi, Sneha Annie Sebastian, Harshan Atwal, Inderjeet Bharaj, Khushal Choudhary, Charles Sineri

    The integration of Artificial Intelligence (AI) in medicine has been revolutionary, particularly in cardiology, where AI offers transformative tools for data integration, image analysis, and predictive modeling. In procedural settings such as percutaneous coronary intervention (PCI) planning, where timely decision-making is crucial, AI represents a promising avenue for real-time risk prediction. However, current clinical scores and risk models often fall short in dynamic environments like the catheterization (cath) lab due to their static nature and limited adaptability to intra-procedural complexities. Emerging AI models aim to leverage high-frequency physiological data, procedural metadata, and multimodal imaging to recognize evolving patterns and anticipate complications. Nevertheless, most existing applications remain retrospective, lack real-time integration, and are constrained by limited external validation. Looking ahead, the implementation of real-time AI systems in the cath lab holds significant potential to enhance procedural safety and outcomes by delivering anticipatory alerts and actionable insights that support clinical decision-making during PCI. However, it is important to note that most currently available AI models remain retrospective or observational in nature, and prospective evidence demonstrating improved clinical outcomes through real-time AI-guided interventions remains limited.

  • Open Access

    Metabolomic Profiling of Tyrosine Kinase Inhibitor-Induced Endothelial Dysfunction and Cardiovascular Toxicity

    by Gurkaranvir Singh, Inderjeet Bharaj, Joey Bettencourt, Amarjit Kaur Sekhon, Gurparvesh Singh, Aaron Sidhu, Emanuel Zayas Diaz, Sulaiman Paika, Ariel De Leon, Ajit Brar, et al.

    Background: Tyrosine kinase inhibitors (TKIs) have transformed cancer therapy; however, they are associated with cardiovascular toxicity. Metabolomics provides a comprehensive framework for identifying early biochemical disruptions that precede clinical manifestations and for formulating mechanism-based intervention strategies. Methods: We conducted a narrative synthesis of published preclinical and translational studies on TKI cardiotoxicity, focusing on untargeted and targeted metabolomic findings and complementary proteomic and transcriptomic data. Functional validation was performed using rodent and cellular models. Mechanistic themes were identified, and implications for biomarker panels, multi-omic integration, and metabolomics-guided interventions were proposed. Conclusions: Metabolomic analyses of various TKIs identified convergent signatures along three interconnected axes: (1) mitochondrial bioenergetic dysfunction characterized by impaired long-chain fatty acid oxidation and adenylate depletion; (2) disruption of endothelial nitric oxide signaling with redox imbalance, including increased nitrotyrosine, Nox activation, and eNOS uncoupling; and (3) an inflammatory metabolic profile marked by elevated branched-chain and aromatic amino acids, creatine, and osmolytes. Rodent models of sunitinib and sorafenib replicate these signatures and demonstrate histological injury, contractile dysfunction, and fibrosis. Preclinical intervention data, particularly restoration of myocardial carnitine, AMPK signaling, and fatty acid oxidation by L-carnitine, provide proof of concept for metabolomics-guided cardioprotection. Metabolomics can identify mechanistic biomarkers that facilitate the early detection, risk stratification, and targeted prevention of TKI-induced cardiovascular injury. Translation into precision cardio-oncology requires prospective validation, standardized assays, and biomarker-driven interventional trials.

  • Open Access

    Percutaneous Retrieval of Migrated Embolization Coils From the Right Atrium

    by Inderjeet Bharaj, Ei Ei Thwe, Inderbir Padda, Hao Pan, Akil Loli, David Prutzman, Basil Alkhatib

  • Open Access

    Cardiac MRI in Identifying Myopericarditis Mimicking STEMI in a Patient with HIV: A Case Report

    by Inderjeet S. Bharaj, Ajit Brar, Billal Mohmand, Michael Morris, Beeletsega T. Yeneneh

    BACKGROUND Acute myopericarditis can clinically and electrocardiographically mimic ST-elevation myocardial infarction (STEMI), leading to misdiagnosis and delayed treatment. In people living with HIV (PLWH), particularly those untreated, impaired immunity and viral-driven inflammation amplify cardiac involvement. Autopsy data suggest a myocarditis prevalence rate of up to 50% in AIDS patients, yet clinically overt cases remain rare. Diagnostic ambiguity can precipitate unnecessary invasive procedures and contribute to HIV-associated cardiomyopathy, an AIDS-defining illness. CASE REPORT A 62-year-old white man with untreated HIV, noncompliance with antiretroviral therapy, heart failure with reduced ejection fraction (HFrEF), and active substance use presented with 3 days of chest pressure and progressive dyspnea. Pre-hospital ECG demonstrated inferolateral ST-segment elevations, triggering STEMI activation. Coronary angiography revealed multivessel obstructive stenoses with preserved TIMI-3 flow and no thrombotic occlusion. Transthoracic echocardiography showed global left ventricular hypokinesis (EF 24%) and moderate pericardial effusion. Cardiac magnetic resonance imaging demonstrated elevated native T1 times, diffuse pericardial enhancement, and absent late gadolinium uptake, confirming acute myopericarditis. Serologic evaluation included coccidioidomycosis titers, viral panel, and tuberculosis workup. Treatment comprised colchicine, ibuprofen, aspirin, high-intensity statin, goal-directed medical therapy for heart failure, reinitiation of antiretroviral therapy, and prophylaxis for opportunistic infections. CONCLUSIONS This case illustrates the diagnostic challenge of distinguishing myopericarditis from STEMI in people living with HIV. Accurate recognition using advanced imaging techniques such as cardiac MRI can prevent unnecessary invasive procedures and facilitate targeted therapy. Multidisciplinary care is vital to optimizing outcomes, particularly in patients with complex comorbidities and barriers to care.

  • Open Access

    Aortoiliac calcification hindering cardiac interventions: A case for intravascular lithotripsy

    by Inderjeet Bharaj, Ei Ei Thwe, Inderbir Padda, Ravi Mann, Baljeet Uppal, Merick Kirshner


  • Open Access

    Contemporary and Emerging Therapeutics in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: In Memory of Professor Akira Endo

    by Inderjeet Singh Bharaj, Ajit Singh Brar, Aayushi Kacheria, Karen Purewal, Austin Simister, Umabalan Thirupathy, Palak Gupta, Jasraj Singh Kahlon, Juzer Munaim, Ei Ei Thwe, et al.

    Cardiovascular-kidney-metabolic (CKM) syndrome is a multifaceted, systemic disorder characterized by the interplay of cardiovascular disease (CVD), chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and obesity. This review synthesizes current and emerging therapeutic strategies aimed at addressing the shared pathophysiologic mechanisms driving CKM progression, such as insulin resistance, inflammation, oxidative stress, and neurohormonal activation. Established pharmacotherapies that include sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and nonsteroidal mineralocorticoid receptor antagonists like finerenone have demonstrated robust efficacy in reducing cardiovascular events, slowing renal decline, and improving metabolic outcomes. Additionally, novel agents targeting lipoprotein(a), interleukin-6, and hepatic fat accumulation are expanding the therapeutic landscape. RNA-based therapies, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), are designed to modulate lipoprotein(a) and PCSK9 expression. Artificial intelligence (AI) is also emerging as a transformative tool for personalized CKM management, enhancing risk prediction and clinical decision-making. The review highlights the relevance of metabolic dysfunction-associated steatotic liver disease (MASLD) as a CKM modifier and discusses the approval of resmetirom, a selective thyroid hormone receptor β agonist, for noncirrhotic MASH. By integrating evidence from clinical trials, mechanistic studies, and emerging technologies, this review provides a comprehensive resource for clinicians and researchers navigating the evolving field of CKM syndrome.

  • Open Access

    Contemporary and Emerging Therapeutics in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: In Memory of Professor Akira Endo

    by Inderjeet Singh Bharaj, Ajit Brar, Aayushi Kacheria, Karen Purewal, Austin Simister, Umabalan Thirupathy, Palak Gupta, Jasraj Kahlon, Juzer Munaim, Ei Ei Thwe, et al.

    Cardiovascular-kidney-metabolic (CKM) syndrome is a multifaceted, systemic disorder characterized by the interplay of cardiovascular disease (CVD), chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and obesity. This review synthesizes current and emerging therapeutic strategies aimed at addressing the shared pathophysiologic mechanisms driving CKM progression, such as insulin resistance, inflammation, oxidative stress, and neurohormonal activation. Established pharmacotherapies that include sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and nonsteroidal mineralocorticoid receptor antagonists like finerenone have demonstrated robust efficacy in reducing cardiovascular events, slowing renal decline, and improving metabolic outcomes. Additionally, novel agents targeting lipoprotein(a), interleukin-6, and hepatic fat accumulation are expanding the therapeutic landscape. RNA-based therapies, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), are designed to modulate lipoprotein(a) and PCSK9 expression. Artificial intelligence (AI) is also emerging as a transformative tool for personalized CKM management, enhancing risk prediction and clinical decision-making. The review highlights the relevance of metabolic dysfunction-associated steatotic liver disease (MASLD) as a CKM modifier and discusses the approval of resmetirom, a selective thyroid hormone receptor β agonist, for noncirrhotic MASH. By integrating evidence from clinical trials, mechanistic studies, and emerging technologies, this review provides a comprehensive resource for clinicians and researchers navigating the evolving field of CKM syndrome.